Assessment of Novel Cardiovascular Biomarkers in Chronic Obstructive Pulmonary Disease

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2024 Nov 29

PMID 39614211

Authors

Kumiko Hiramatsu

Takashi Motegi

Keiko Morii

Kozui Kida

Affiliations

Soon will be listed here.

Abstract

Background: Cardiovascular disease is a common comorbidity in chronic obstructive pulmonary disease (COPD) and pre-COPD patients, contributing significantly to morbidity and mortality. We aimed to investigate whether Galectin-3 (Gal-3) levels correlate with cardiovascular biomarkers and cardiopulmonary function in COPD and pre-COPD patients to assess its potential role as a marker for cardiovascular comorbidity.

Methods: Community-dwelling adults with and without COPD were recruited. Biomarkers including Gal-3, high-sensitivity cardiac troponin T (hs-cTnT), and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured. Subjects underwent pulmonary function tests, chest CT, echocardiograms, and a 6-minute walking test. The relationships between biomarkers and cardiopulmonary function were examined.

Results: Among 120 subjects (97 COPD, 23 pre-COPD), the mean age was 70.2 years, and the mean predicted forced expiratory volume in 1 s (FEV1%) was 68.5%. Gal-3 levels averaged 1733.7 pg/mL. Gal-3 significantly correlated with NT-proBNP (ρ = 0.229, p = 0.012) and negatively with maximal pulse rate during the 6-minute walking test (ρ=-0.185, p = 0.043). No significant correlation was found between Gal-3 and hs-cTnT levels. However, hs-cTnT levels showed significant negative correlations with age (ρ=-0.526, p < 0.001), FEV1% (ρ=-0.373, p < 0.001), E/A ratio (ρ=-0.390, p < 0.001), and walking distance (ρ=-0.444, p < 0.001), and positive correlations with deceleration time (ρ = 0.299, p = 0.001), right ventricular systolic pressure (ρ = 0.197, p = 0.037), and high-sensitivity C-reactive protein (ρ = 0.212, p = 0.020).

Conclusions: Gal-3 levels show correlations with NT-proBNP and maximal pulse rate, supporting its investigation as a potential marker for cardiovascular comorbidity in COPD and pre-COPD populations.

References

Alqahtani J, Aldhahir A, Alghamdi S, Al Ghamdi S, AlDraiwiesh I, Alsulayyim A . A systematic review and meta-analysis of heart rate variability in COPD. Front Cardiovasc Med. 2023; 10:1070327. PMC: 9981678. DOI: 10.3389/fcvm.2023.1070327. View

Sundqvist M, Andelid K, Ekberg-Jansson A, Bylund J, Karlsson-Bengtsson A, Linden A . Systemic Galectin-3 in Smokers with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis: The Impact of Exacerbations. Int J Chron Obstruct Pulmon Dis. 2021; 16:367-377. PMC: 7903965. DOI: 10.2147/COPD.S283372. View

Travers J, Kamal F, Robbins J, Yutzey K, Blaxall B . Cardiac Fibrosis: The Fibroblast Awakens. Circ Res. 2016; 118(6):1021-40. PMC: 4800485. DOI: 10.1161/CIRCRESAHA.115.306565. View

Wannamethee S, Welsh P, Papacosta O, Ellins E, Halcox J, Whincup P . Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes. Atherosclerosis. 2017; 264:36-43. PMC: 5603971. DOI: 10.1016/j.atherosclerosis.2017.07.008. View

Araya J, Saito N, Hosaka Y, Ichikawa A, Kadota T, Fujita Y . Impaired TRIM16-Mediated Lysophagy in Chronic Obstructive Pulmonary Disease Pathogenesis. J Immunol. 2021; 207(1):65-76. DOI: 10.4049/jimmunol.2001364. View

Mullerova H, Agusti A, Erqou S, Mapel D . Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013; 144(4):1163-1178. DOI: 10.1378/chest.12-2847. View

Xue M, Guo Z, Cai C, Sun B, Wang H . Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia. Respiration. 2019; 98(6):534-545. DOI: 10.1159/000503689. View

Horodinschi R, Bratu O, Dediu G, Pantea Stoian A, Motofei I, Diaconu C . Heart failure and chronic obstructive pulmonary disease: a review. Acta Cardiol. 2019; 75(2):97-104. DOI: 10.1080/00015385.2018.1559485. View

Pilette C, Colinet B, Kiss R, Andre S, Kaltner H, Gabius H . Increased galectin-3 expression and intra-epithelial neutrophils in small airways in severe COPD. Eur Respir J. 2007; 29(5):914-22. DOI: 10.1183/09031936.00073005. View

10.

Hattori K, Ishii T, Motegi T, Kusunoki Y, Gemma A, Kida K . Relationship between serum cardiac troponin T level and cardiopulmonary function in stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015; 10:309-20. PMC: 4330031. DOI: 10.2147/COPD.S76293. View

11.

Graham B, Steenbruggen I, Miller M, Barjaktarevic I, Cooper B, Hall G . Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019; 200(8):e70-e88. PMC: 6794117. DOI: 10.1164/rccm.201908-1590ST. View

12.

Fabbri L, Celli B, Agusti A, Criner G, Dransfield M, Divo M . COPD and multimorbidity: recognising and addressing a syndemic occurrence. Lancet Respir Med. 2023; 11(11):1020-1034. DOI: 10.1016/S2213-2600(23)00261-8. View

13.

Hara A, Niwa M, Noguchi K, Kanayama T, Niwa A, Matsuo M . Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules. 2020; 10(3). PMC: 7175224. DOI: 10.3390/biom10030389. View

14.

Rabe K, Hurst J, Suissa S . Cardiovascular disease and COPD: dangerous liaisons?. Eur Respir Rev. 2018; 27(149). PMC: 9488649. DOI: 10.1183/16000617.0057-2018. View

15.

Bonnans C, Chou J, Werb Z . Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014; 15(12):786-801. PMC: 4316204. DOI: 10.1038/nrm3904. View

16.

Chen W, Thomas J, Sadatsafavi M, FitzGerald J . Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015; 3(8):631-9. DOI: 10.1016/S2213-2600(15)00241-6. View

17.

Singh S, Puhan M, Andrianopoulos V, Hernandes N, Mitchell K, Hill C . An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J. 2014; 44(6):1447-78. DOI: 10.1183/09031936.00150414. View

18.

Zaborska B, Sygitowicz G, Smarz K, Pilichowska-Paszkiet E, Budaj A . Galectin-3 is related to right ventricular dysfunction in heart failure patients with reduced ejection fraction and may affect exercise capacity. Sci Rep. 2020; 10(1):16682. PMC: 7542167. DOI: 10.1038/s41598-020-73634-8. View

19.

Besler C, Lang D, Urban D, Rommel K, von Roeder M, Fengler K . Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker. Circ Heart Fail. 2017; 10(3). DOI: 10.1161/CIRCHEARTFAILURE.116.003804. View

20.

Andrejic O, Vucic R, Pavlovic M, McClements L, Stokanovic D, Jevtovic-Stoimenov T . Association between Galectin-3 levels within central and peripheral venous blood, and adverse left ventricular remodelling after first acute myocardial infarction. Sci Rep. 2019; 9(1):13145. PMC: 6739356. DOI: 10.1038/s41598-019-49511-4. View